CoChat

[177Lu‐DOTA0‐Tyr3]‐Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

Swärd, Christina, Bernhardt, Peter, Ahlman, Håkan, Wängberg, Bo, Forssell‐Aronsson, Eva, Larsson, Maria, Svensson, Johanna, Rossi‐Norrlund, Rauni, Kölby, Lars · 2010 · World Journal of Surgery
Cited by 68

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: Peptide receptor radiation therapy (PRRT) using [177 Lu‐DOTA 0‐Tyr 3]‐octreotate is a new, promising option for treatment of disseminated gastroenteropancreatic neuroendocrine tumors (GEPNETs). Methods: During 2006‐2008, 26 patients with disseminated GEPNETs were treated with 177 Lu‐octreotate. Radiologic response (RECIST), biochemical response [plasma chromogranin‐A (P‐CgA)], hematologic toxicity [Common Toxicity Criteria (CTC)], absorbed dose to the kidneys (conjugate view method), and glomerular filtration rate (GFR) were analyzed. Results: 177 Lu‐octreotate (8 GBq) was given one to five times (median = 3) with a 6‐week interval between each. Sixteen of the 26 patients were evaluated radiologically; 6 (38%) had partial response (PR), 8 (50%) had stable disease (SD), and 2 (13%) had progressive disease (PD). Seventeen of the 26 patients were evaluated biochemically; 6 (35%) showed a ≥30% decrease, 8 (47%) showed a ≥20% increase, and 3 (18%) showed neither a ≥30% decrease nor a ≥20% increase. The mean absorbed dose to the kidneys was 24 Gy. With a dose limit of 27 Gy to the kidneys, 10 patients did not receive the planned four treatments, while four patients had the potential to receive additional treatment. A significant reduction (p = 0.0013) of GFR was observed at follow‐up. Three patients experienced CTC grade 3 hematologic toxicity. Conclusions: By using the absorbed dose to the kidneys as a limiting factor, treatment with 177 Lu‐octreotate can be individualized, e.g., overtreatment can be avoided and patients with the potential to receive additional treatment can be identified. Further studies are needed to define tolerance doses to the kidneys so that treatment can be optimized.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00268-009-0387-6

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 68

Metadata

Authors
Swärd, C., Bernhardt, P., Ahlman, H., Wängberg, B., Forssell‐Aronsson, E., Larsson, M., Svensson, J., Rossi‐Norrlund, R., & Kölby, L.
Venue
World Journal of Surgery
Publisher
Wiley
Published
2010-01-12
Volume
34
Issue
6
Pages
1368-1372
ISSN
  • 0364-2313 (ISSN-L)
  • 1432-2323
OpenAlex
W2028793063
Cited by
68
References
1
FWCI
2.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: [177Lu‐DOTA0‐Tyr3]‐Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney. https://app.cochat.ai/papers/10.1007/s00268-009-0387-6
The paper
Swärd, C., Bernhardt, P., Ahlman, H., Wängberg, B., Forssell‐Aronsson, E., Larsson, M., Svensson, J., Rossi‐Norrlund, R., & Kölby, L. (2010). [177Lu‐DOTA0‐Tyr3]‐Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney. World Journal of Surgery. https://doi.org/10.1007/s00268-009-0387-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.